A microfluidic gradient generator for faster personalized medicine

Scientists from National Taiwan University and the National Institutes of Applied Research of Taiwan have developed a rapid and accurate microfluidic device that generates precise drug gradients and outperforms manual dilution, enabling reliable multi-drug screening for high-throughput and personalized medicine.

Cancer remains one of the world’s most urgent health challenges, with the World Health Organization reporting 20 million new cases and 9.7 million deaths in 2022. As global cancer incidence is projected to exceed 35 million cases by 2050, the need for effective and personalized treatment strategies continues to intensify.

A major obstacle in cancer therapy is tumor heterogeneity, which leads to patient-specific drug responses and frequent development of drug resistance. This makes it essential not only to develop new therapeutics but also to rapidly evaluate optimal drug doses and combinations using reliable screening platforms.

Traditional drug screening relies heavily on manual pipetting and serial dilutions, which are labor-intensive, prone to cumulative errors, and difficult to scale. Although high-throughput screening systems have improved testing capacity, they still face significant limitations—particularly in generating accurate concentration gradients needed to determine key pharmacological parameters such as IC₅₀ and Emax. Even small dilution errors can distort drug-response curves and compromise clinical relevance.

To address these challenges, researchers have developed a high-throughput microfluidic device capable of rapidly producing precise drug concentration gradients. Unlike diffusion-based or droplet-microfluidic methods that are slow, unstable, or equipment-dependent, the new system uses controlled laminar flow in microchannels to adjust concentration ratios through simple channel-length engineering.

This approach achieves highly accurate gradients that remain stable regardless of flow rate changes, reaching steady state within 30 seconds. The study is published in the Chemical Engineering Journal.

In validation studies using BSA solutions and cancer drug assays, the device produced concentration gradients with less than 6% deviation from theoretical values—far outperforming manual dilution. Cytotoxicity tests with oxaliplatin on HCT-116 colorectal cancer cells showed only a 2.45% IC₅₀ difference compared to traditional methods. Multi-drug screening with 5-FU, oxaliplatin, and SN-38 further demonstrated consistent detection of synergistic effects.

The device’s outlet design is compatible with standard 96-well plates, allowing seamless integration into existing screening workflows. Future work aims to apply the system to patient-derived organoids, potentially advancing precision oncology and personalized therapeutic strategies.

“By reducing labor, minimizing human error, and enabling rapid, reliable drug testing, this microfluidic platform significantly accelerates the cancer drug development pipeline,” says Chien-Fu Chen, Ph.D., co-corresponding author and a distinguished professor at the Institute of Applied Mechanics, National Taiwan University.